Persistence to antihypertensive drug classes in uncomplicated hypertension: a nationwide Swedish cohort studyShow others and affiliations
2026 (English)In: eClinicalMedicine, E-ISSN 2589-5370, Vol. 91, article id 103696Article in journal (Refereed) Published
Abstract [en]
Background Only half of patients appear adherent to antihypertensive treatment. If so, the effectiveness in prevention against adverse cardiovascular outcomes may depend more on a drugs' side effects than its blood pressure effects. We hypothesized that initiating treatment with a particular antihypertensive drug class will determine later persistence. Methods We applied a new-user trial emulation approach to multiple mandatory health-care registers in Sweden. All individuals starting antihypertensive treatment with an angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEi), calcium channel blocker (CCB), thiazide/thiazide-like diuretic (TD), or single-pill combination of two drugs (SPC) in 2011-2018 were assessed for inclusion. Patients with prior cardiovascular disease or diabetes were excluded. Persistence was defined using dispensed prescription refills with at least 80% adherence. We applied multistate Poisson regression models adjusting for age, sex, obesity, birth country, education, income, marital status and year of initiation. The study period was January 1st 2011-December 31st 2019. Findings A total of 341,182 patients were included. Initiating antihypertensive treatment with an ARB was associated with a larger proportion continuing their original drug class, or indeed any antihypertensive drug class, at any time during the five years of follow-up. At three years, 44.7% (CI 43.7-45.7) of the ARB initiators were continuously persistent to their original drug class. The corresponding number if intermittent discontinuations were allowed was 81.8% (CI 80.9-82.8). Overall, if intermittent discontinuations and changes between classes were allowed, about 80% of all new users of antihypertensive drugs (regardless of class at initiation) were persistent to at least one antihypertensive drug class over 5 years. Interpretation Initiating treatment with an ARB is associated with the best long-term class persistence and least treatment changes. The "rule of halves" should be replaced with the insight that, after the first year, at least 4 out of 5 patients take their antihypertensive drug at least 4 out of 5 days. Copyright (c) 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Place, publisher, year, edition, pages
ELSEVIER , 2026. Vol. 91, article id 103696
Keywords [en]
Persistence; Medication adherence; Antihypertensive agents; Register study; Hypertension; First-line; drug choice
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:liu:diva-221135DOI: 10.1016/j.eclinm.2025.103696ISI: 001677277600001PubMedID: 41625962OAI: oai:DiVA.org:liu-221135DiVA, id: diva2:2037330
Note
Funding Agencies|Geriatric Foundation, Uppsala Sweden; Swedish Research Council [sens2020005, sens2020598, 2018-05973]
2026-02-102026-02-102026-03-31